MedTrace Logo

Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients

NCT01399450 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2019-04-09

No results posted yet for this study

Summary

The purpose of this study is changing (improving), after initiating various doses of Paliperidone ER on schizophrenia patients.

Conditions

Interventions

DRUG

paliperidone

paliperidone augmenting on ongoing medication

Sponsors & Collaborators

  • Johnson & Johnson

    collaborator INDUSTRY

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Yong Min Ahn, MD, PhD · Seoul National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2016-07-31
Completion
2016-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01399450 on ClinicalTrials.gov